RXi nets $13.7mm through public offering

RXi Pharmaceuticals Corp. netted $13.7mm through an upsized public offering. The company sold 3.7mm units at $0.70 apiece (each unit consisted of one common share and a seven-year common share purchase warrant exercisable at $0.70) and also sold 17.7mm pre-funded units at $0.69 (each pre-funded unit held one pre-funded warrant for a common share and one seven-year common share purchase warrant exercisable at $0.70). Proceeds will support continued development of RXi's immuno-oncology projects.